Functional upregulation of the DNA cytosine deaminase APOBEC3B by polyomaviruses

Journal of Virology

Volumn 90, Issue 14, 2016, Pages 6379-6386

  Verhalen, Brandy ^a   Starrett, Gabriel J ^b   Harris, Reuben S ^b,c   Jiang, Mengxi ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3B ENZYME; CYTOSINE DEAMINASE; UNCLASSIFIED DRUG; VIRUS DNA; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; BK VIRUS INFECTION; CONTROLLED STUDY; DISEASE ACTIVITY; DNA REPLICATION; ENZYME ACTIVITY; ENZYME ASSAY; GENOME ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; POLYOMAVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS GENOME; VIRUS IDENTIFICATION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY TUBULE; METABOLISM; PATHOGENICITY; PATHOLOGY; POLYOMAVIRUS INFECTION; TRANSCRIPTION INITIATION; VIROLOGY; VIRUS REPLICATION;

CELLS, CULTURED; CYTIDINE DEAMINASE; GENE EXPRESSION REGULATION; GENOME, VIRAL; HUMANS; KIDNEY TUBULES; MINOR HISTOCOMPATIBILITY ANTIGENS; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; VIRUS REPLICATION;

EID: 84977498107     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00771-16     Document Type: Article

References (43)

1. Doerries K. 2006. Human polyomavirus JC and BK persistent infection. Adv Exp Med Biol 577:102-116. http://dx.doi.org/10.1007/0-387-32957-9_8.
2. DeCaprio JA, Garcea RL. 2013. A cornucopia of human polyomaviruses. Nat Rev Microbiol 11:264-276. http://dx.doi.org/10.1038/nrmicro2992.
3. Bennett SM, Broekema NM, Imperiale MJ. 2012. BK polyomavirus: emerging pathogen. Microbes Infect 14:672-683. http://dx.doi.org/10.1016/j.micinf.2012.02.002.
4. Papadimitriou JC, Randhawa P, Rinaldo CH, Drachenberg CB, Alexiev B, Hirsch HH. 2016. BK polyomavirus infection and renourinary tumorigenesis. Am J Transplant 16:398-406. http://dx.doi.org/10.1111/ajt.13550.
5. Wollebo HS, White MK, Gordon J, Berger JR, Khalili K. 2015. Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560-570. http://dx.doi.org/10.1002/ana.24371.
6. Chang Y, Moore PS. 2012. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol 7:123-144. http://dx.doi.org/10.1146/annurev-pathol-011110-130227.
7. Cheng J, Rozenblatt-Rosen O, Paulson KG, Nghiem P, DeCaprio JA. 2013. Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. J Virol 87:6118-6126. http://dx.doi.org/10.1128/JVI.00385-13.
8. Giacobbi NS, Gupta T, Coxon AT, Pipas JM. 2015. Polyomavirus T antigens activate an antiviral state. Virology 476:377-385. http://dx.doi.org/10.1016/j.virol.2014.12.032.
9. Abend JR, Low JA, Imperiale MJ. 2010. Global effects of BKV infection on gene expression in human primary kidney epithelial cells. Virology 397:73-79. http://dx.doi.org/10.1016/j.virol.2009.10.047.
10. Yogo Y, Sugimoto C, Zhong S, Homma Y. 2009. Evolution of the BK polyomavirus: epidemiological, anthropological and clinical implications. Rev Med Virol 19:185-199. http://dx.doi.org/10.1002/rmv.613.
11. Gjoerup O, Chang Y. 2010. Update on human polyomaviruses and cancer. Adv Cancer Res 106:1-51. http://dx.doi.org/10.1016/S0065-230X(10)06001-X.
12. Wendzicki JA, Moore PS, Chang Y. 2015. Large T and small T antigens of Merkel cell polyomavirus. Curr Opin Virol 11:38-43. http://dx.doi.org/10.1016/j.coviro.2015.01.009.
13. Harris RS, Dudley JP. 2015. APOBECs and virus restriction. Virology 479-480:131-145.
14. Vieira VC, Soares MA. 2013. The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int 2013: 683095.
15. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N, Takaori-Kondo A. 2012. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep 2:806.
16. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. 2013. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366-370. http://dx.doi.org/10.1038/nature11881.
17. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, Getz G, Gordenin DA. 2013. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45: 970-976. http://dx.doi.org/10.1038/ng.2702.
18. Burns MB, Temiz NA, Harris RS. 2013. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45:977-983. http://dx.doi.org/10.1038/ng.2701.
19. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, Davies HR, Knappskog S, Martin S, Papaemmanuil E, Ramakrishna M, Shlien A, Simonic I, Xue Y, Tyler-Smith C, Campbell PJ, Stratton MR. 2014. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBECdependent mutations in breast cancer. Nat Genet 46:487-491. http://dx.doi.org/10.1038/ng.2955.
20. Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA. 2015. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 47:1067-1072. http://dx.doi.org/10.1038/ng.3378.
21. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, Stephens PJ, McLaren S, Butler AP, Teague JW, Jonsson G, Garber JE, Silver D, Miron P, Fatima A, Boyault S, Langerod A, Tutt A, Martens JW, Aparicio SA, Borg A, Salomon AV, Thomas G, Borresen-Dale AL, Richardson AL, Neuberger MS, Futreal PA, Campbell PJ, Stratton MR, Breast Cancer Working Group of the International Cancer Genome Consortium. 2012. Mutational processes molding the genomes of 21 breast cancers. Cell 149:979-993. http://dx.doi.org/10.1016/j.cell.2012.04.024.
22. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, Lee D, Soares MA, Lambert PF, Howley PM, Harris RS. 2014. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. mBio 5:e02234-14. http://dx.doi.org/10.1128/mBio.02234-14.
23. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. 2014. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833-1841. http://dx.doi.org/10.1016/j.celrep.2014.05.012.
24. Jiang M, Zhao L, Gamez M, Imperiale MJ. 2012. Roles of ATM and ATRmediated DNA damage responses during lytic BK polyomavirus infection. PLoS Pathog 8:e1002898. http://dx.doi.org/10.1371/journal.ppat.1002898.
25. Low J, Humes HD, Szczypka M, Imperiale M. 2004. BKV and SV40 infection of human kidney tubular epithelial cells in vitro. Virology 323: 182-188. http://dx.doi.org/10.1016/j.virol.2004.03.027.
26. Jiang M, Abend JR, Tsai B, Imperiale MJ. 2009. Early events during BK virus entry and disassembly. J Virol 83:1350-1358. http://dx.doi.org/10.1128/JVI.02169-08.
27. Verhalen B, Justice JL, Imperiale MJ, Jiang M. 2015. Viral DNA replication-dependent DNA damage response activation during BK polyomavirus infection. J Virol 89:5032-5039. http://dx.doi.org/10.1128/JVI.03650-14.
28. Bollag B, Mackeen PC, Frisque RJ. 1996. Purified JC virus T antigen derived from insect cells preferentially interacts with binding site II of the viral core origin under replication conditions. Virology 218:81-93. http://dx.doi.org/10.1006/viro.1996.0168.
29. Jiang M, Entezami P, Gamez M, Stamminger T, Imperiale MJ. 2011. Functional reorganization of promyelocytic leukemia nuclear bodies during BK virus infection. mBio 2:e00281-10. http://dx.doi.org/10.1128/mBio.00281-10.
30. Leonard B, McCann JL, Starrett GJ, Kosyakovsky L, Luengas EM, Molan AM, Burns MB, McDougle RM, Parker PJ, Brown WL, Harris RS. 29 September 2015. The PKC/NF-kappaB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res http://dx.doi.org/10.1158/0008-5472.CAN-15-2171-T.
31. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539.
32. Ebrahimi D, Anwar F, Davenport MP. 2011. APOBEC3 has not left an evolutionary footprint on the HIV-1 genome. J Virol 85:9139-9146. http://dx.doi.org/10.1128/JVI.00658-11.
33. Moens U, Rasheed K, Abdulsalam I, Sveinbjornsson B. 2015. The role of Merkel cell polyomavirus and otherhumanpolyomaviruses in emerging hallmarks of cancer. Viruses 7:1871-1901. http://dx.doi.org/10.3390/v7041871.
34. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85:11220-11234. http://dx.doi.org/10.1128/JVI.05238-11.
35. Hoelzer K, Shackelton LA, Parrish CR. 2008. Presence and role of cytosine methylation in DNA viruses of animals. Nucleic Acids Res 36:2825-2837. http://dx.doi.org/10.1093/nar/gkn121.
36. Haradhvala NJ, Polak P, Stojanov P, Covington KR, Shinbrot E, Hess JM, Rheinbay E, Kim J, Maruvka YE, Braunstein LZ, Kamburov A, Hanawalt PC, Wheeler DA, Koren A, Lawrence MS, Getz G. 2016. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164:538-549. http://dx.doi.org/10.1016/j.cell.2015.12.050.
37. Hoopes JI, Cortez LM, Mertz TM, Malc EP, Mieczkowski PA, Roberts SA. 2016. APOBEC3A and APOBEC3B preferentially deaminate the lagging strand template during DNA replication. Cell Rep 14:1273-1282. http://dx.doi.org/10.1016/j.celrep.2016.01.021.
38. Seplyarskiy VB, Soldatov RA, Popadin KY, Antonarakis SE, Bazykin GA, Nikolaev SI. 2016. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. Genome Res 26:174-182. http://dx.doi.org/10.1101/gr.197046.115.
39. Bhagwat AS, Hao W, Townes JP, Lee H, Tang H, Foster PL. 2016. Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in Escherichia coli. Proc Natl Acad Sci U S A 113: 2176-2181. http://dx.doi.org/10.1073/pnas.1522325113.
40. Haché G, Mansky LM, Harris RS. 2006. Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev 8:148-157.
41. Monajemi M, Woodworth CF, Benkaroun J, Grant M, Larijani M. 2012. Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology 9:35. http://dx.doi.org/10.1186/1742-4690-9-35.
42. Warren CJ, Doorslaer KV, Pandey A, Espinosa JM, Pyeon D. 2015. Role of the host restriction factor APOBEC3 on papillomavirus evolution. Virus Evol 1:vev015. http://dx.doi.org/10.1093/ve/vev015.
43. Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, Lambert PF, Santiago ML, Pyeon D. 2015. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 89:688-702. http://dx.doi.org/10.1128/JVI.02383-14.